Mitoquinol/IDX-1: does it help (esp w/fatigue)?

#1

And what are some of the best sources? Why does it need to be refrigerated?

#2

Prompt:

Role: Longevity doctor, biologist, and endocrinologist. Task: Identify the science and clinical evidence on the health benefits, and fatique benefits of Mitoquinol / IDX-1

Claude Opus 5.5 Response:

I’ll pull the forum thread, then check the primary literature on mitoquinol (MitoQ) and IDX-1 for clinical evidence on health and fatigue outcomes.

Bottom line

For fatigue, the human evidence does not support mitoquinol. The one placebo-controlled trial in a fatigue-defined population (ME/CFS) was null, the MS fatigue trials have no published efficacy results that I could find, and exercise studies show no performance gain. The best-supported human benefit is improved endothelial function in older adults, and that rests on small trials with surrogate endpoints.

I could not identify “IDX-1”. The forum thread is a single post from today with no product details, and searches return only an unrelated pancreatic transcription factor. I treated it as a mitoquinol product, so everything below is MitoQ (mitoquinol mesylate) data. If IDX-1 is a different formulation or a gray-market source, none of it transfers automatically.

Mechanism

MitoQ is a ubiquinol-like antioxidant attached to a triphenylphosphonium cation, which drives its accumulation at the inner mitochondrial membrane. The fatigue hypothesis is that less mitochondrial ROS means better ATP production. Two findings cut against that:

  • In endothelial cells at 150 to 500 nM, mitoquinol lowered ATP-linked oxygen consumption and increased proton leak (MedChemExpress summary).
  • In immune cells from ME/CFS patients, CoQ10 improved mitochondrial function, while MitoQ at the concentration used caused major uncoupling (Otago thesis).

Both are in vitro, and concentration matters, but an antioxidant that can also uncouple is not an obvious energy enhancer.

Fatigue evidence

Population Design Result Grade
ME/CFS and fibromyalgia Two randomized, blinded, placebo-controlled crossover studies, 20 mg/day for 6 weeks No benefit in ME/CFS unless patients knew they were on the active supplement; possible pain and working memory signal in fibromyalgia C, null for fatigue
MS fatigue, OHSU (NCT03166800) Randomized, 20 or 40 mg vs placebo, 12 weeks Terminated with 9 participants enrolled; uninformative No usable data
MS fatigue, Portland VA (NCT04267926) Double-blind, 45 enrolled, 20 or 40 mg vs placebo Completion listed as March 2026; I found no published efficacy results Pending
Long COVID (NCT05373043) Exercise rehab plus MitoQ or placebo, estimated 300 participants No results located Pending
Exercise performance Meta-analysis of randomized trials Lower exercise-induced oxidative damage (SMD -1.33, 95% CI -2.24 to -0.43) but no improvement in aerobic performance; possible exercise tolerance benefit in peripheral artery disease A for the biomarker, null for function
Fatigue in animal models Mouse Gulf War Illness and cancer cachexia models Improved activity and strength in treated mice D, translational gap

On the SMD of -1.33: a standardized mean difference expresses the gap between groups in standard deviations, and anything past 0.8 counts as large. So MitoQ clearly moves an oxidative stress marker, yet that large biomarker change produced no measurable performance change. That dissociation is the central finding for anyone taking it for energy.

Confidence that mitoquinol meaningfully reduces fatigue in a generally healthy adult: low, roughly 10 to 15 percent. Confidence that open-label reports of benefit are largely expectancy: moderately high, given the ME/CFS result above.

Other health outcomes

  • Vascular function (strongest signal). In 20 healthy adults aged 60 to 79 with impaired endothelial function, 6 weeks of 20 mg/day in a double-blind crossover gave 42% higher flow-mediated dilation than placebo (Rossman 2018). A meta-analysis of mitochondria-targeted antioxidants found improved flow-mediated dilation across 3 trials (SMD 1.19, 95% CI 0.28 to 2.16) with very low evidence certainty (Mason 2022). The effect is large on paper, but the interval is wide and there are no hard cardiovascular outcomes. Note that the Rossman study was funded by NIH and MitoQ Limited. Grade B to C.
  • Liver. A 28-day trial in 30 hepatitis C patients at 40 or 80 mg/day showed a significant ALT decrease versus baseline. Short, small, and never followed by a phase 3. Grade C.
  • Parkinson’s disease. In 128 newly diagnosed patients, 40 or 80 mg/day had no effect on progression over 12 months. Grade B, null.
  • Lifespan. MitoQ did not significantly affect lifespan in UM-HET3 mice in the NIA Interventions Testing Program. As far as I know that test used a single dose, so it is not exhaustive, but there is no positive longevity signal to set against it.

Safety

  • GI effects are dose-limiting. In the Parkinson’s trial, discontinuations were 13 at 80 mg, 2 at 40 mg and 1 on placebo, mostly gastrointestinal.
  • At supplement doses, tolerability looks close to placebo. In a small asthma trial, reflux or nausea occurred in 7 of 20 on MitoQ versus 5 of 18 on placebo.
  • Kidney signal, in vitro only. At 500 nmol/L, MitoQ caused rapid mitochondrial swelling and depolarization in proximal tubule cells, a mechanism unrelated to its antioxidant activity and probably due to the alkyl chain inserting into the inner membrane (Gottwald 2018). No human renal harm has been shown, but it argues against megadosing.
  • The manufacturer advises against use during cancer chemotherapy, after recent organ transplantation, and in pregnancy or breastfeeding.

The thread’s other questions

Refrigeration: research-grade mitoquinol mesylate is specified for storage at -20°C, sealed and away from moisture, consistent with a reduced quinol that oxidizes readily. Branded MitoQ capsules are sold as shelf-stable, as far as I know through a stabilized formulation. A product that requires refrigeration is likely unformulated or minimally formulated material, which raises questions about purity and how much has already oxidized to mitoquinone.

Sourcing: the trials used branded MitoQ, typically 20 mg daily, and absorption is significantly reduced by food, hence the empty-stomach instruction. Chemical-supplier material is labeled research use only, not for human consumption.

Clinical read

For someone with unexplained fatigue, a workup (thyroid, ferritin, B12, sleep apnea, depression, medications) has far higher yield than mitoquinol. If someone wants to try it anyway, a 6 to 8 week trial of 20 mg/day of the branded product with a pre-specified outcome is a reasonable n-of-1; the ME/CFS data suggest blinding yourself if possible. This is a reading of the evidence rather than individual medical advice.

Sources: